Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma.

Reni, M; Cereda, S; Bonetto, E; Viganò, M G; Passoni, P; Zerbi, A; Balzano, G; Nicoletti, R; Staudacher, C; Di Carlo, V

Reni, M; Cereda, S; Bonetto, E; Viganò, M G; Passoni, P; Zerbi, A; Balzano, G; Nicoletti, R; Staudacher, C; Di Carlo, V.

Affiliation

Reni M; Department of Oncology, San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, Italy. reni.michele@hsr.it

Cancer Chemother Pharmacol ; 59(3): 361-7, 2007 Feb.

Article in En | MEDLINE | ID: mdl-16807732

Subject(s)

Adenocarcinoma/drug therapy; Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Pancreatic Neoplasms/drug therapy; Adenocarcinoma/mortality; Adenocarcinoma/pathology; Adult; Aged; Cisplatin/administration & dosage; Deoxycytidine/administration & dosage; Deoxycytidine/analogs & derivatives; Dose-Response Relationship, Drug; Epirubicin/administration & dosage; Female; Fluorouracil/administration & dosage; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms/mortality; Pancreatic Neoplasms/pathology; Survival Rate; Gemcitabine

Search on Google

XML

PubMed Links

Collection: 01-internacional Health context: 3_ND / 4_TD / 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Pancreatic Neoplasms / Adenocarcinoma / Antineoplastic Combined Chemotherapy Protocols Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Cancer Chemother Pharmacol Year: 2007 Document type: Article

Search on Google

XML

PubMed Links